Published • loading... • Updated
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance Its Oncology Strategy
Lupin will keep a significant stake and seed funding as Kaveri Therapeutics seeks capital for global trials of two cancer programs.
- On Tuesday, July 21, 2026, Lupin Limited announced the strategic spin-out of two oncology programs, LNP7457 and LNP8701 , into Kaveri Therapeutics Inc., retaining an 82.2% equity stake.
- Under the licensing agreement, Lupin Inc. granted Kaveri an exclusive perpetual license for both oncology programs while providing seed funding to support global clinical development.
- Both programs demonstrated encouraging clinical progress and reported positive data at the American Society of Clinical Oncology meetings in 2025 and 2026, targeting solid tumors including lung, pancreatic, and ovarian cancers.
- Kaveri Therapeutics will operate under Chief Executive Officer Kristi Jones and Chief Medical Officer Robert Pierce, who will lead the company's clinical development strategy.
- "We are proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics," said Lupin CEO Vinita Gupta, emphasizing the partnership's aim to bring meaningful innovation to patients.
Insights by Ground AI
17 Articles
17 Articles
Lupin Licenses Oncology Programs to Kaveri Therapeutics for Growth
Lupin Limited has licensed two oncology drug programs to Kaveri Therapeutics for $1.6 million. This deal, completed in July 2026, gives Lupin an 82.2% stake in Kaveri. The programs will undergo global clinical trials under Kaveri Therapeutics, led by CEO Kristi Jone.
·India
Read Full Article
Lupin Licenses Two Cancer Drug Programmes to Kaveri Therapeutics for USD 1.6 Million
Get latest articles and stories on Business at LatestLY. Lupin Limited's wholly owned US subsidiary, Lupin Inc., has licensed two oncology drug programmes to newly established American firm Kaveri Therapeutics Inc. for USD 1.6 million, the company said in a regulatory filing. Business News | Lupin Licenses Two Cancer Drug Programmes to Kaveri Therapeutics for USD 1.6 Million.
·Mumbai, India
Read Full Article
Coverage Details
Total News Sources17
Leaning Left4Leaning Right4Center8Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 25%
C 50%
R 25%
Factuality
To view factuality data please Upgrade to Premium
